Upstream Bio, Inc. (UPB) stock
UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.78−0.08 (-2.80%)
Close on Nov 13, 2026Market cap $152.26MP/E –Yield –
Upstream Bio cash
Cash and short-term investments held at the end of each period.
Upstream Bio's cash was $207.37M at Sep 30, 2026. For fiscal 2025 it was $341.51M, down 27.4% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $341.51M | -27.4% |
| FY2024 | Dec 31, 2024 | $470.45M | +328.4% |
| FY2023 | Dec 31, 2023 | $109.81M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $207.37M | -44.3% |
| Q2 FY2026 | Jun 30, 2026 | $261.31M | -33.6% |
| Q1 FY2026 | Mar 31, 2026 | $294.58M | -31.7% |
| Q4 FY2025 | Dec 31, 2025 | $341.51M | -27.4% |
| Q3 FY2025 | Sep 30, 2025 | $372.43M | +68.8% |
| Q2 FY2025 | Jun 30, 2025 | $393.58M | +731.5% |
| Q1 FY2025 | Mar 31, 2025 | $431.38M | +1269.0% |
| Q4 FY2024 | Dec 31, 2024 | $470.45M | +328.4% |
| Q3 FY2024 | Sep 30, 2024 | $220.66M | +366.3% |
| Q2 FY2024 | Jun 30, 2024 | $47.34M | – |
| Q1 FY2024 | Mar 31, 2024 | $31.51M | – |
| Q4 FY2023 | Dec 31, 2023 | $109.81M | – |
| Q3 FY2023 | Sep 30, 2023 | $47.32M | – |
See a number that looks wrong?